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Abstract
Background: Postoperative fluid management in critically ill neonates and infants with capillary leak syndrome
(CLS) and extensive volume overload after cardiac surgery on cardiopulmonary bypass is challenging. CLS is often
resistant to conventional diuretic therapy, aggravating the course of weaning from invasive ventilation, increasing
length of stay on ICU and morbidity and mortality.
Methods: Tolvaptan (TLV, vasopressin type 2 receptor antagonist) was used as an additive diuretic in neonates and
infants with CLS after cardiac surgery. Retrospective analysis of 25 patients with CLS including preoperative and
postoperative parameters was performed. Multivariate regression analysis was performed to identify predictors for
TLV response.
Results: Multivariate analysis identified urinary output during 24 h after TLV administration and mean blood
pressure (BP) on day 2 of TLV treatment as predictors for TLV response (AUC = 0.956). Responder showed greater
weight reduction (p < 0.0001), earlier weaning from ventilator during TLV (p = 0.0421) and shorter time in the ICU
after TLV treatment (p = 0.0155). Serum sodium and serum osmolality increased significantly over time in all patients
treated with TLV.
Conclusion: In neonates and infants with diuretic-refractory CLS after cardiac surgery, additional aquaretic therapy
with TLV showed an increase in urinary output and reduction in bodyweight in patients classified as TLV responder.
Increase in urinary output and mean BP on day 2 of treatment were strong predictors for TLV response.
Introduction
Regulation of volume and electrolyte homeostasis after
cardiac surgery on cardiopulmonary bypass (CPB) in new-
borns and infants with congenital heart defects (CHD) is
challenging [1, 2]. The use of CPB during open heart sur-
gery is accompanied by an inflammatory response leading
to capillary leak syndrome (CLS) [3–5]. CLS can be de-
fined by the clinical presentation of third space volume
overload with consecutive generalized edema and substan-
tial gain of weight, intravascular hypovolemia,
hypoalbuminemia and hemoconcentration in the absence
of severe congestive heart failure (CHF). In conjunction,
an elevation of subcutaneous-thoracic ratio (ST-ratio) can
help to diagnose CLS in the pediatric population [3, 4, 6,
7]. Prolonged interstitial fluid retention due to CLS is
often resistant to conventional diuretic therapy, aggravat-
ing weaning from invasive ventilation, leading to longer
time at the ICU and increasing postoperative morbidity
(e.g. pulmonary infections) and mortality [4, 8, 9]. There
have been great efforts in early detection and prevention
of CLS [3, 10]. However, improvements in treatment strat-
egies especially for neonates and children after cardiac
surgery are still needed.* Correspondence: julia.moosmann@uk-erlangen.de1Department of Pediatric Cardiology, University of Erlangen-Nürnberg,
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Tolvaptan (TLV) is a selective competitive vasopressin
2 receptor antagonist and prohibits the movement of
aquaporin 2 into the luminal wall of the collecting duct
and thereby reduces the reabsorption of water [11, 12].
TLV has been FDA (Food and Drug Administration) ap-
proved for the treatment of hyponatremia associated
with CHF in adults and the syndrome of inappropriate
antidiuretic hormone secretion (SIADH) in adults and
children. The approval for treatment of hyponatremia in
patients with liver cirrhosis was removed due to re-
ported hepatotoxicity in adults, and the duration of
treatment was limited to 30 days. TLV has also shown
efficacy in treatment of autosomal-dominant polycystic
kidney disease [12–16].
Several studies including a phase III study illustrated the
efficacy of TLV in CHF with hypervolemia and hyponatre-
mia especially during the acute phase of cardiac decom-
pensation and diuretic resistance in adults [17–19]. The
multicenter, retrospective J-SPECH study from 2015 sug-
gested that TLV can be safely administered in pediatric pa-
tients but may be less effective in neonates and infants
compared to adolescence or adults [14, 20]. Differences in
the response profiles to TLV were often seen, however
they had been unpredictable in the beginning. Recent
studies defined TLV response as an increase of urine vol-
ume after its administration, patients responding with an
increase are defined as responder [21, 22].
The role of TLV in postoperative fluid management
after cardiac surgery on CPB has been evaluated in post-
operative treatment in adults, but little is known about
its role in infants and neonates [18, 23, 24]. One recent
retrospective study in pediatric patients after uncompli-
cated cardiovascular surgery (shunt closure) compared
treatment of additional TLV to patients treated with
standard diuretic therapy [25]. TLV treatment was safely
administered and resulted in an increase in urinary out-
put, showing a potential reduction of intravenous
loop-diuretic use during treatment course [25].
We used TLV in the postoperative fluid management
in critically ill infants and neonates with postoperative
CLS, massive volume overload and diuretic resistance
after complex cardiac surgery and we retrospectively an-
alyzed parameters to predict TLV response.
Materials and methods
Patients
Our retrospective analysis encompasses a single center
experience (Department of Pediatric Cardiology at the
Friedrich-Alexander-University of Erlangen-Nürnberg,
Germany). We included 25 patients with CHD after car-
diac surgery, treated with TLV in ICU between June
2011 and May 2017, evaluating effects of postoperative
TLV therapy in patients with CLS. Criteria for the use of
add-on therapy was 1) fluid overload 2) no increase in
urinary output under conventional diuretic therapy 3)
persisting renal function (no anuria) 4) low serum so-
dium. Descriptive patient’s auxologic and clinical charac-
teristics, leading cardiologic diagnosis and the respective
surgical procedures are displayed in Tables 1 and 2. Our
cohort included four preterm patients (1: 31 + 6; 2: 35 +
6; 3: 34 + 5; 4: 34 + 5). Corrected age for preterm infants
at TLV treatment was 35 + 3, 39 + 5, 41 + 0 and one in-
fant received therapy 8 month after birth.
We evaluated Risk Adjusted Congenital Heart Surgery
score (RACHS-1) [26, 27] and basic Aristotle score [28]
to quantify risk and complexity of the performed surger-
ies. STS-EACTS mortality category and associated major
complications (95% CrI) were implemented to express
mortality associated with congenital heart surgery and
classifying congenital heart surgery procedures on the
basis of their potential for morbidity [29, 30]. Team of
surgeons, anesthesiologists and pediatric cardiologists
remained unchanged during the study period. All pa-
tients underwent median sternotomy. Post-operative
treatment was exclusively supervised on the pediatric
cardiology ICU, beat-to-beat circulatory and pulmonary
status, fluid and electrolyte homeostasis was digitally
monitored, clinical status and organ function was moni-
tored and digitally documented routinely by critical care
nursing staff. Co-medication including conventional di-
uretic therapy before and during the treatment course
with TLV was analyzed.
Definition of CLS, responder- and non-responder –
grouping
CLS was defined by clinical symptoms (volume overload,
intravascular hypovolemia, low total protein, hypoalbu-
minemia, hemoconcentration) and subcutaneous-thoracic
ratio (ST-Ratio; > 97. percentile). ST-Ratio was evaluated
to quantify CLS by chest x-ray with anterior-posterior
beam path [6]. X-rays were documented with Web Ris
(celsius37.com AG, Mannheim, Germany).
Responder to TLV were classified according to the def-
inition from adult studies by Imamura et al. [21, 22, 31]
“responders as patients with any increase in urine volume
(UV) at day 1 when TLV administration was started”. To
classify individuals as responder in our population to TLV
we permitted an increase of > 10% in urinary output
within 24 h after the first TLV administration. Others were
classified as non-responder [20–22].
Treatment protocol
TLV (“Samsca”, Otsuka, Japan) was administered as indi-
vidual healing attempt in critically ill children with com-
plicated postoperative course. Off-label use was
explained and informed consent was obtained by all par-
ticipating families. Starting dose of TLV was 25% of tar-
get dose (1 mg/kg/d). Dose finding was titrated based on
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clinical symptoms, side effects (see below) and serum so-
dium levels. Tablets are available in 15mg and 30 mg.
Provision of small dosages was performed by the depart-
ment of pharmacology of the University hospital Er-
langen. Tablets were pulverized and encapsulated. At the
ICU the pulverized aliquots were diluted and adminis-
tered via nasogastric tube.
Definition of TLV related adverse events
Adverse events were retrospectively analyzed accord-
ing to the criteria of Otsuka applying for the planned
Phase 3b, multicenter study trial “effects of TLV in
hospitalized children with euvolemic or hypervolemic
serum hyponatremia”.
Adverse events are classified: 1) absolute serum so-
dium level > 145 mmol/L or an overly rapid rise in serum
sodium level (an increase in serum sodium of > 8 mmol/
L over a 10-h period, 12 mmol/L over a 24-h period. 2)
neurological symptoms, or other signs or symptoms sug-
gestive of osmotic demyelination. 3) worsening symp-
toms of hyponatremia. 4) elevations in AST or ALT that
are > 2 x ULN (upper limit of normal) or levels that in-
crease > 2 times their previously observed level.
Data collection
TLV doses were calculated in mg/kg (preoperative
weight)/d. Volume overload was quantified, assuming
preoperative weight as 100%. TLV application period,
time on mechanical ventilation, time until extubation,
body weight, urinary output and total daily dose of se-
lected concurrent medications were recorded by Inte-
grated Care Manager (ICM, Drägerwerk AG & Co.
KGaA, Lübeck, Germany) software solutions. Retro-
spective data acquisition of laboratory values before sur-
gery, before TLV treatment and during TLV treatment
was performed using Lauris (version 15.09.29.9, Swisslab
GmbH, Berlin, Germany) (Table 1).
Institutional protocol for transfusion and fluid
management
Post-operative indication for transfusion was alike and
followed our departmental transfusion algorithm: packed
red blood cells (PRBC) were administered at a
Table 1 Patient demographics
Parameter CLS P-
valueResponder Non-responder
n 17 8
Female 9 4 1.0000
Male 8 4
Gestagional age (SSW) 37 + 4 (31 + 6–40 + 1) 38 + 1(37 + 1–40 + 0) 0.1049
RACHS-1score 3 (2–6) 3 (2–6) 0.2253
Basic Aristotle score 10 (4–15) 7.25 (6.5–14.5) 0.0997
Cardiopulmonary bypass time (min) 219 (0–390) 148 (56–439) 0.1709
Cross clamp time (min) 77 (0–177) 51 (8–173) 0.3508
Subcutaneous-thoracic-ratio (%) 21.0 (14.3–26.5) 19.75 (14.7–27.9) 0.6408
Secondary chest closure after surgery (days) 8 (2–24) (n = 11) 10 (2–17) (n = 4) 0.9878
Start of TLV after surgery (days) 13 (2–44) 15 (7–24) 1.0000
Age when TLV therapy was started (days) 35 (9–228) 37.5 (20–549) 0.3821
Preoperative weight (kg) 3.30 (1.88–4.27) 3.20 (1.93–6.32) 0.7487
Absolute weight before TLV (kg) 4.35 (2.83–5.55) 4.42 (2.61–5.68) 0.8673
Weight above dry weight when TLV was started (%) 131.8 (102.6–202.8) 133.5 (113.5–154.4) 0.8151
Dose of TLV administration (mg/kg) 0.53 (0.15–1.06) 0.49 (0.13–0.95) 0.6204
Period of TLV administration (days) 8 (1–25) 7 (1–47) 0.6391
Urinary output 24 h prior to Tolvaptan administration (ml/kg/h) 4.15 (0.92–9.18) 3.27 (0.54–9.40) 0.4665
Urinary output 24 h after Tolvaptan administration (ml/kg/h) 6.38 (1.20–15.41) 2.21 (0.28–7.15) 0.0039
Days on ICU after TLV administration 15 (3–111) 40.5 (16–139) 0.0155
Death 1 3 0.0808
Frequencies are given for binary data; for quantitative and ordinal data median and range are presented. p < 0.05 has been considered as statistically significant
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hemoglobin (Hb) level of 14 g/dl in cyanotic patients
and 10 g/dl in non-cyanotic patients. In the case of
on-going bleeding, fresh frozen plasma (FFP, 10-15 ml/
kg) was transfused if quick reached below 50%. Platelets
were transfused at a platelet count below 50 × 103/μl.
Postoperative indication for fluid substitution of kris-
talloids (NaCl and Jonosteril) is central venous pressure
(CVP) < 5, and low blood pressure (BP) according to age
related reference ranges. Administration of colloidal vol-
ume expanders, i.e. albumin and hydroxyethyl starch
(HAES) is performed in hemodynamically unstable cases
or low serum albumin levels.
Statistical analysis
Quantitative approximately normally distributed vari-
ables are expressed as mean ± standard deviation (SD).
For ordinally scaled data (e.g. RACHS-1) and for vari-
ables with skewed distribution median value together
with minimum and maximum are given. As most of
variables in Table 1 (demographic parameters,
co-medication and laboratory parameters) and 3
(co-medication and laboratory parameters) seem to be
normally distributed and due to the rather small sam-
ple sizes non-parametric Mann-Whitney-U tests have
been performed in order to compare the median
values of the two groups. For qualitative factors (i.e.
cardiac malformation or procedures) absolute fre-
quencies are presented. Fisher’s exact tests have been
used.
In order to investigate changes over time (regard-
ing weight, serum sodium, osmolality, and urinary
output) ANOVAs for repeated measurements have
been performed including time point and responder
group as fixed factors and patients’ ID as a random
factor. For the liver enzymes, Friedman’s test was
performed instead of ANOVA for repeated measure-
ments, because of the skewed distribution. Multiple
regression analysis including all parameters was per-
formed to identify predictive parameters for TLV
responder.
Table 2 Diagnosis and surgical procedures
Diagnosis Operation Responder Non-
responder
STS-EACTS mortality
category
Major complications
(95%CrI)
Aortic arch hypoplasia Reconstruction of the aortic arch 1 3 12.2%
Dextro Transposition of the great
arteries (d-TGA)
Arterial switch operation + ASD and/or
VSD closure
4 3 10.7%
Arterial switch operation + VSD patch
and aortic arch repair
1 5 31.0%
Pulmonary atresia RVOT patch- enlargement 1 2 6.5%
Single ventricle Norwood 2 5 29.7%
Bidirectional Glenn-anastomosis 1 1 2 6.4%
aortic arch reconstruction 1 1 4 15.9%
DKS anastomosis + aortic arch
reconstruction
1 5 22.9%
Fallot-Tetralogy (TOF) TOF repair (RVOT patch, VSD patch) 1 1 1 7.7%
Blalock-Taussig-Shunt 1 4 12.4%
Interrupted aortic arch aortic arch repair 1 1 4 19.0%
Double outlet right ventricle (DORV) Closure of aorto-pulmonary-window 1 2 6.2%
Norwood 1 5 29.7%
Tricuspid atresia Ib Aorto-pulmonary shunt 1 4 11.3%
Total anomalous pulmonary venous
return (TAPVC)
Correction of pulmonary vein anomalies 1 1 4 16.4%
Mitral valve insufficiency Mitral valve reconstruction, Ring
implantation
1 2 6.6%
Total 17 8
Mean 3.4 15.3%
Responder 4 12.4%
Non responder 3 9.5%
Values are expressed as absolute frequencies for binary data
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All statistical analyses were conducted using GraphPad
Prism (version 6.05, GraphPad Software, Inc., La Jolla,
CA 92037 USA) and SAS, release 9.4 (SAS institute Inc.,
Cary. NC, USA). The result of a statistical test has been
considered as statistically significant if the p value was
less than 0.05.
Ethical statement
The retrospective study was approved by the ethics com-
mittee of the University of Erlangen-Nürnberg (Re.-No.
145_13B). The study was conducted in accordance with
the Declaration of Helsinki [32].
Results
Demographics
Postoperative CLS was diagnosed in 25 patients after
cardiac surgery. Clinical parameters to define CLS are
displayed in Table 1.
According to the definition of TLV responder by Ima-
mura et al. [21, 22, 31] 17 individuals were identified as
responder to TLV defined by an increase in urinary out-
put > 10% in 24 h and 8 infants were identified as
non-responder [20–22] (Table 1).
Age was similar in both groups (median 35 and 37.5
days; p = 0.3821). The underlying cardiac malformation
and surgical procedures are displayed in Table 2. Extra-
cardiac malformations and syndromes were Trisomy 21
in one responder and one non-responder patient, Turner
syndrome in one non-responder and omphalocele in one
responder patient. Surgical parameters (cardio pulmon-
ary bypass (CPB) time, cross clamp time and surgical
risk scores RACHS-1 and Aristotele score) are displayed
in Table 1. In 15 patients, primary chest closure was not
possible and secondary closure was performed. Both
groups presented with increased ST-ratio > 97. percentile
(p = 0.6408). A significant positive correlation was identi-
fied between ST-ratio and time on CPB (p = 0.0305,
Pearson‘s correlation coefficient r = 0.4333). STS-EACTS
mortality category was 4 in responder and 3 in
non-responder (p = 0.2201) and estimated major compli-
cation rates are 15.3% in responder compared to 12.4%
in non-responder (p = 0.2190). Four responder patients
showed severe infection with elevated procalcitonin
(PCT) (n = 1 necroticing enterocolitis, n = 1 positive
blood culture with Straphylococcus epidermidis, n = 1
pneumonia with Enterococcus faecalis, n = 1 Entero-
coccus faecium wound infection). Infection rates normal-
ized before TLV treatment in all responder patients. One
non-responder patient presented with an infection
during treatment (n = 1 Staphylococcus epidermidis in
intraoperative pericardial swab). Postoperative major
complications are demonstrated in Table 3.
Postoperative days on ICU, before TLV therapy was
started (p = 1.0000), preoperative weight (p = 0.7487) and
absolute weight (p = 0.8673) when TLV was started were
not significantly different between responder and
non-responder. All individuals presented with increased
body-weight with a median of 131.8% over their preopera-
tive weight in the responder group and 133.5% in the
non-responder group, when TLV was started (p = 0.8151).
The duration of TLV application (p = 0.6391) and average
dose of TLV (p = 0.6204) administered were similar. Me-
dian length of stay in the ICU after TLV administration
was significantly shorter in responder compared to
non-responder patients (15 vs. 40.5 days; p = 0.0155).
We observed four deaths in the study population, one
responder and three non-responder (p = 0.0808.) 17 days,
34 days, 35 days and 48 days after starting TLV.
Laboratory parameters were analyzed at several time
points. Preoperative parameters did not show signifi-
cant differences between both groups (Additional file
1: Table S1). Before TLV treatment non-responder
group presented with a higher hematocrit (p = 0.0169)
and higher hemoglobin level (p = 0.0168). According
to CLS criteria: total protein was lowered in both
groups (responder: 37.0 g/l and non-responder: 38.84
g/l; p = 0.9303) and median albumin levels were de-
creased in responder 20.15 g/l and non-responder
Table 3 Major complications
Responder Non-Responder p-value
Postoperative acute renal failure requiring temporary dialysis
Hemodialysis 1/17 (10 days) 1/8 (18 days) 1.0000
PD 6/17 (10 days; 3–19) 6/8 (10 days; 4–29) 0.1936/ 0.8099
Postoperative neurologic deficit 1/17 1/8 1.0000
Postoperative mechanical circulatory support 5/17 (8 days; 4–12) 5/8 (12 days; 7–34) 0.1936 /0.2073
Phrenic nerve injury 3/17 1/8 1.0000
Unplanned reoperation 2/17 3/8 0.2833
Major complications according to the Society of Thoracic Surgeons. Values are expressed as median and range. p < 0.05 has been considered as statistically
significant.Fisher-Test was used to compare numbers of complications in both groups, Mann-Whitney-U-Test was used for differences between durations
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21.50 g/l (p = 0.7983). Serum sodium levels were low/
normal in both groups (responder: 135 mmol/l vs.
130.5 mmol/l; p = 0.1269). No differences were ob-
served for serum blood urea nitrogen (BUN), creatin-
ine, potassium and serum osmolality before TLV
treatment was started (Table 4).
Vital parameters including (BP, heart rate (HR) and
CVP) were analyzed. CVP decreased during TLV
treatment in both groups, but was not significantly
different. Mean BP was lower in non-responder on
day 2 (p = 0.0035) and day 3 (p = 0.0309) of treatment
(Additional file 1: Table S2).
Predicting TLV response
Multivariate regression analysis to predict TLV response
revealed mean BP on day 2 of TLV administration and
urinary output 24 h after TLV as significant combined
predictors for responder to TLV. Predicting TLV re-
sponse with an AUC = 0.956.
The probability for TLV response increases by 1.185 /
mmHg mean BP on day 2 of TLV treatment and the prob-
ability for TLV response increases by factor 2.064 / ml/kg/
h urinary output after 24 h after TLV administration.
Mathematical model to estimate the probability for
responder:
Tolvaptan effects on bodyweight, serum sodium levels,
osmolality and urinary output
For each parameter (bodyweight, serum sodium,
osmolality and urinary output) and for each group
(responders, non-responders) changes over time
could be observed (with the only exception for the
weight parameter in the non-responder group)
(Fig. 1a-d).
Responders showed a significant weight reduction
starting at day # 2 after TLV administration. The greatest
weight reduction was achieved at day # 7 of treatment
down to 115.6 ± 7.1% (p < 0.0001) of preoperative weight.
Fig. 1a shows the weight progression between responder
and non-responder group over 10 days of TLV adminis-
tration. Non-responder did not show a significant weight
reduction in the investigated time period (p = 0.1067),
while responders showed a significant weight reduction
(p < 0.0001) (Fig. 1).
Urinary output 24 h after the first dose of TLV was
significantly higher (by definition of responder) in
the responder group (p = 0.0039; Table 1; Fig. 1d).
During all 10 days of treatment urinary output stayed
higher (related to day 0) in the responder group. In
the non-responder group urinary output also in-
creased over the total investigated time period (p =
0.0003), but a significant increase from day # 0 was
Table 4 Co medication and laboratory parameters
Responder Non responder P-value
Co-medication (mg/kg/day) when TLV was started
Furosemide perfusor 5.93 (0.60–7.98) (n = 16) 5.57 (1.70–10.9) (n = 8) 0.1522
Thiazide oral 1.93 (0.99–3.72) (n = 12) 1.03 (0.46–2.09) (n = 5) 0.1703
Spironolactone oral 2.27 (0.93–6.38) (n = 13) 2.08 (2.05–2.78) (n = 4) 0.7339
Etacrynacid intravenous 1.09 (0.69–3.41) (n = 5) 1.15 (1.04–1.26) (n = 2) 1.0000
Laboratory parameters before TLV treatment
Hematocrit (%) 40.07 (31.73–53.60) 44.08 (39.87–51.37) 0.0169
Hemoglobin (g/dl) 13.12 (9.5–19.02) (n = 16) 14.25 (13.40–16.83) 0.0168
Total protein (g/l) 37.0 (27–45.67) 38.84 (31.67–44.00) 0.9303
Albumin (g/l) 20.15 (18.43–26.40) (n = 7) 21.50 (17.8–25.0) (n = 7) 0.7983
serum BUN (mg/dl) 42.00 (7.67–113.50) 50.83 (24.33–109.17) 0.4316
Creatinine (mg/dl) 0.44 (0.24–1.47) 0.66 (0.25–1.02) 0.4484
Sodium (mmol/l) 135 (129–144) 130.5 (126.17–137.67) (n = 7) 0.1269
Potassium (mmol/l) 4.10 (3.63–4.80) 4.09 (3.80–4.60) 0.8156
Osmolality (mosm/kg) 281.67 (267.5–307.0) (n = 16) 280.92 (261.0–291.0) 0.4258
For quantitative and ordinal data median and range are presented. p < 0.05 has been considered as statistically significant
probability for response to TLV ¼ expð−12:34þ 0:1696mean bp day 2 of TLV þ 0:7248
}urinary output 24h after TLV Þ
1−ð expð−12:34þ 0:1696mean bp day 2 of TLV þ 0:7248 }urinary output 24h after TLV ÞÞ
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later than in the responder group on day 7 and 8 of
treatment (Fig. 1d).
Before TLV therapy, responder and non-responder
presented with median serum sodium at the lower
cut off to normal. A significant increase was identi-
fied during the investigated time period in both
groups (p < 0.0001) (Fig. 1b). No significant difference
between responder and non-responder groups was ob-
served (p = 0.5489, accumulated over time), however
the response profiles were different (p < 0.0001). In re-
sponder, a significant increase of serum sodium was
seen at day # 3, in non-responder at day # 4. In the
responder group, hypernatremia was not observed.
We observed one adverse event related to TLV in the
non-responder group, one patient developed hyperna-
tremia (151 mmol/l) on day # 9, which was reversible
on the following day.
Osmolality increased in both groups over treatment
course (non-responder p < 0.0001 and responder p =
0.001) (Fig. 1c). Significant changes in osmolality were
seen on day # 4 in the non-responder and on day # 5 in
the responder group (Fig. 1c).
Liver metabolism
Liver enzymes were monitored before, during and after
TLV treatment course. Due to the limitations of retrospect-
ive data analysis measurements were not performed on a
regular basis of a distinct study protocol. Regarding the
Fig. 1 Weight (a), serum sodium (b), serum osmolality (c) and urinary output (d) during 10 days of TLV treatment. Responders (red graph) and
non-responder (black graph); * p < 0.05 (related to day 0) ** p < 0.01 (related to day 0) *** p < 0.001 (related to day 0). p-values deriving from 2
way ANOVAs; p values for time effect deriving from 2 separate ANOVAS for responders and non-responders. Changes over time regarding
bodyweight, serum sodium, osmolality and urinary output have been tested using ANOVAs for repeated measurements with group (responder /
non-responder) and time point as fixed factors. The p-values in Table 2 reveal that for each parameter interactions between group and time
effects could be observed indicating that response profiles of the two groups differ (see Fig. 1a and d)
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upper cut off values of alanine- aminotransferase (ALT;
normal < 26U/l), aspartate- aminotransferase (AST; normal
< 50U/l) and Gamma-Glutamyltransferase (GGT; normal
< 23U/l), 3/8 of the responder, 4/8 of the non-responder
presented with significantly elevated GGT before TLV treat-
ment, already. 2/8 of non-responder presented with initial
AST elevation. ALT elevation was present in 3/8 of the
non-responder. In both groups no significant elevation of
AST, ALT and GGT was identified for median group pa-
rameters during and after treatment (Table 5).
Co-medication, transfusions and fluid management
Diuretic and catecholamine therapy before surgery is listed
in Additional file 1: Table S1 presenting no differences be-
tween both groups. Postoperative catecholamine therapy
and diuretic treatment before TLV administration was not
different between responder and non-responder (Additional
file 1: Table S3). Intravenous additional diuretic therapy
could be reduced in both groups during treatment course
with TLV (by factor 3.68 and 3.77, respectively). An
ANOVA for repeated measurements revealed no statistical
difference between the responders and non-responders (p
= 0.3935) and no statistically significant interaction term (p
= 0.6127). However, reduction over the investigated time
could be observed in both groups (p < 0.0001). Nephrotoxic
medication (i.e. vancomycin, fluconazole and tobramycin)
was administered in a subset of patients in both groups, no
differences were observed (Additional file 1: Table S3). Esti-
mated glomerular filtration rate (GFR; by Schwartz for-
mula) before and during treatment is provided in Table 6.
All patients received postoperative kristalloids, substitution
during TLV and after TLV is listed in Additional file 1:
Table S3 and did not show differences between both
groups. Only a very limited number of patients received
kolloids, mainly albumin. HAES was only substituted in
two non-responder patient during the immediate postoper-
ative course (Additional file 1: Table S3).
Airway management
Mechanical or non-invasive ventilation was required in
all CLS patients (Table 6). All 17 responder patients
needed mechanical ventilation before TLV administra-
tion. In 10 patients, invasive ventilation could be ended
during TLV administration. In 2 responder patients,
extubation was performed within 7 days after TLV. 3 in-
dividuals were extubated more than 7 days after TLV
treatment course. 2 patients were not extubated and re-
ceived a tracheostoma. In the non-responder group, 7
patients required mechanical ventilation, only one of
them could be extubated during treatment course with
TLV. Horovitz-index (oxygenation index) demonstrates
improvements of respiration therapy and increased dur-
ing treatment (Table 6). It was higher in responder com-
pared to non-responder but did not show significant
differences. Rate of extubation during TLV treatment
was higher in responder compared to non-responder (p
= 0.0421, Table 6).
Discussion
We report a retrospective analysis of our single center
experience with TLV treatment in infants and neonates
after cardiac surgery with postoperative CLS to predict
TLV response. Additional diuretic therapy with TLV in-
creased urinary output > 10% in 2/3 of patients with
CLS. According to the definition of Imamura et al. [21,
22, 31] patients with increased urinary output during the
first 24 h, were classified as responder to TLV and pre-
sented with significant reduction in body weight. In-
crease in urinary output during the first 24 h after TLV
administration and higher mean BP on day 2 of TLV
treatment were identified as predictive factors for TLV
response (AUC = 0.956).
The underlying mechanisms of TLV response have been
studied in detail; TLV is able to antagonize antidiuretic hor-
mone (ADH) overstimulation and thus increases urinary
output due to aquaresis. ADH excretion can be triggered by
intravascular hypovolemia, activation of renin angiotensin
aldosterone (RAAS) axis (mainly angiotensin II, by chronic
extensive diuretic abuse), reduced osmotic pressure (plasma
osmolality <275mmosm/kg), stress and post-operative pain
[33, 34]. All these parameter can be observed in pediatric
patients with CLS due to long CPB time, presenting with
third space volume overload and intravascular volume de-
pletion and therefore no severe hyponatremia but low to
normal serum sodium levels. In contrast, patients with post-
operative renal or cardiac failure presenting with volume
Table 5 Liver metabolism
Group Parameter Before TLV Under TLV After TLV P-value
Responder (n = 17) GGT (< 23 U/l) 41.5 (19–93)n = 8 95.5 (29–215) n = 6 118 (38–354) n = 9 0.2926
Non-responder (n = 8) 53.5 (17–220) 93 (34–352) n = 7 116.5 (24–845) n = 6 0.2223
Responder (n = 17) AST (< 50 U/l) 22.5 (10–48) n = 8 20.5 (10–57) n = 8 23.5 (14–143) n = 10 0.4576
Non-responder (n = 8) 32.5 (11–638) 57 (14–252) n = 6 28.5 (13–50) 0.1677
Responder (n = 17) ALT (< 26 U/l) 16 (9–30) n = 7 14 (6–178) n = 9 17.5 (10–26) n = 8 0.4987
Non-responder (n = 8) 30.5 (11–382) 51 (7–399) n = 7 21.5 (6–107) 0.1303
Normal values for GGT, AST and ALT are expressed. Values are expressed as median and range. p < 0.05 has been considered as statistically significant
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overload and intravasal hypervolemia and low serum so-
dium. We observed that the aquaretic TLV is not only ef-
fective in patients with hyponatremia and volume overload
due to e.g. cardiac failure as shown earlier, but in especially
in small neonates and infants with CLS including massive
volume overload in the third space and almost normal so-
dium levels. In this group the additional aquaresis mobilized
the volume from the third space and increase urinary out-
put. In patients with intravasal hypervolemia and low serum
sodium, intravascular volume is mobilized. In patients with
CLS serum osmolality remains steady, supporting this
physiologic hypothesis.
Diverse parameters are discussed to predict the response
profiles to TLV however a gold standard has not been
established [22, 35, 36]. Especially for our study population
of neonates and infants no detailed criteria or predictors for
TLV response are known. Thus, one aim of this study was
to identify predictors for TLV response in this patient
population. In our study cohort we identified urinary out-
put during the first 24 h and mean BP on day 2 of TLV
treatment as good predictors for TLV response. Patients
presenting with an increase of urinary output by 1ml/kg/h,
the probability for TLV response increases by factor 2.1.
Further, higher mean BP on day 2 increases the probability
of factor 1.2 by each mmHg. Taken together, both parame-
ters represent strong predictors for TLV response.
One potential explanation could be that increased mean
BP at the beginning of TLV therapy in combination with
the mechanisms of TLV described above supported and
increased TLV effect leading to increased urinary output.
On the other side, all other parameters including electro-
lytes and renal parameters (creatinine, BUN), fluid substitu-
tion, transfusions and concomitant medication etc. are not
regarded as predictors after multiple regression analysis.
Nevertheless, statements about renal function and
GFR are of limited power while using Schwartz formula
which is critically discussed as valid parameter for calcu-
lating neonatal GFR. Cystatin C which was not routinely
measured seems a more predictable parameter to esti-
mate GFR in this patient population. The influence of
other potential confounders such as (e.g. PD, adjunctive
medication) cannot be completely ruled out, partly due
to limited number of patients.
Most likely the response to TLV is also influenced by
age, concomitant medication and degree of heart failure.
As our study has some limitations because of its retro-
spective study design and because of the low sample size
further studies to identify LTV predictors are necessary.
When comparing responder and non-responder: re-
sponder patients presented with significant reduction in
body weight and reduction of additional standard diur-
etic during the TLV treatment course. Further, responder
patients showed an improvement of their clinical course
by earlier weaning from the ventilator and shorter time
on ICU. Nevertheless, these parameters need critical
evaluation in a randomized and blinded trial including
an untreated control group to validate a positive effect
of TLV on outcome parameters.
Table 6 Airway management and GFR
Responder Non-responder p-value
Mechanical ventilation 17 7 0.3200
Non-invasive ventilation 0 1 0.3200
Extubation during TLV 10 1 0.0421
Extubation 2–7 days after TLV 2 0 1.0000
Extubation > 7 days after TLV 3 3 0.3442
No Extubation and tracheostoma 2 3 0.2833
Oxygenation index
Postoperative 173 (45–365) 137 (38–253) 0.0857
Before TLV 235 (127–366) 139 (83–284) 0.0702
1st day 241 (103–377) 162 (132–243) 0.1829
2nd day 264 (110–355) 181 (103–272) 0.0524
3rd day 209 (98–374) 139 (125–266) n = 5 0.4274
Before extubation 255 (167–355) 214 (118–331) n = 3 0.5708
Glomerular filtration rate (GFR)
Preoperative 37 (28–101) 39 (15–114) 0.8531
Postoperative 34 (25–81) 36 (22–73) 0.4833
Before TLV 41 (17–97) 38 (20–108) 0.5774
5 days after begin of TLV 49 (22–105) 39 (20–62) 0.2811
Frequencies are given for binary data; for quantitative and ordinal data median and range are presented. p < 0.05 has been considered as statistically significant
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In the responder group the main effect of TLV treatment
was noticeable during the first 5–6 days. Short-term treat-
ment after cardiovascular surgery might be advantageous
compared to long-term treatment due to a discussed TLV
escape [13]. In patients who do not show an increase in
urinary output (non-responder) a longer treatment should
be critically discussed and possibly terminated to reduce
potential side effects of TLV in pediatric population.
Side effects of TLV are well described by Otsuka
Pharmaceutical and in the literature for adult patients.
Nevertheless, pharmacodynamics in children and infants
can differ severely from adults and randomized trials are
missed in the pediatric population. Despite safety of TLV
therapy was not the aim of the study: in our evaluation de-
scribed side effects were retrospectively analyzed between
the two subgroups. TLV was well tolerated particularly in
terms of excessive sodium elevations or severe deterior-
ation of liver function which did not occur. We had one
case of hypernatremia which was reversible after one day.
All patients receiving TLV showed high morbidity and
mortality, therefore adverse effects especially on renal and
cardiac impairment and long-term outcome could not be
evaluated and need further evaluation in a prospective,
randomized and blinded trial including an appropriate
control group to validate a positive effect of TLV on out-
come compared to standard care.
Conclusion
The use of TLV added to conventional diuretic therapy
in infants and neonates after cardiac surgery with CLS
was effective in 68% of our patients with CHD and CLS
after cardiac surgery. Responder to TLV presented with
increase in urinary output and significant weight reduc-
tion. Reduction of diuretic co-medication was possible.
Increase in urinary output during 24 h after TLV treat-
ment and mean BP on day 2 of treatment were strong
predictors for TLV response. Prospective, controlled and
multicenter studies are desirable and needed to confirm
the beneficial effects of TLV and to monitor side effects
in the field of pediatric cardiology and neonates.
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